NUDT15 and acute lymphoblastic leukemia: Using this system (in a large series of BCP‐ALL and T‐ALL cell lines), we verified the association of both wild‐type NUDT15 genotype and NT5C2 and PRPS1 mutations with a resistance to 6MP at concentrations pharmacologically relevant to the clinical setting.